Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sintilimab plus platinum-based doublet chemotherapy for locally advanced HPV-positive oropharyngeal squamous carcinoma (single-arm phase II)
ChiCTR2200058650Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in oropharyngeal squamous cell carcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Major pathological response rate and Safety. Started Apr 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2200058650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058650.